CME/CE

Host: Carole Bitar, MD, FAAD Guest: Matthew P. Giannetti, MD Guest: Benjamin Ungar, MD On-demand webcast featuring expert-informed best practices for diagnosing and managing patients with systemic mastocytosis (SM) as well as the latest data on new and emerging SM therapies.

Host: Carole Bitar, MD, FAAD Guest: Matthew P. Giannetti, MD Guest: Benjamin Ungar, MD On-demand webcast featuring expert-informed best practices for diagnosing and managing patients with systemic mastocytosis (SM) as well as the latest data on new and emerging SM therapies.

Host: Anton P. Porsteinsson, MD Guest: Vijay K. Ramanan, MD, PhD Watch this webcast exploring the evolving landscape of early Alzheimer’s disease (AD) detection and treatment and highlighting the role of cognitive screening, fluid biomarkers, and emerging therapies. Gain expert insights on recent data from CTAD 2025, including blood-based diagnostics, lifestyle intervention trials, antiamyloid ant...

Host: Anton P. Porsteinsson, MD Guest: Vijay K. Ramanan, MD, PhD Watch this webcast exploring the evolving landscape of early Alzheimer’s disease (AD) detection and treatment and highlighting the role of cognitive screening, fluid biomarkers, and emerging therapies. Gain expert insights on recent data from CTAD 2025, including blood-based diagnostics, lifestyle intervention trials, antiamyloid ant...

Faculty: María-Victoria Mateos, MD, PhD Faculty: Luciano Costa, M.D., Ph. D. This educational activity examines the growing evidence supporting bispecific antibodies in earlier treatment lines of multiple myeloma. Experts discuss the rationale for upstream use of bispecific antibodies and review key data from pivotal trials highlighting the evolving role for bispecific antibodies as early-line tre...

Faculty: Kevin J Harrington, PhD, FRCP, FRCR, FRSB Faculty: Cristina Rodriguez, MD This online educational activity provides clinicians with an in-depth review of the latest findings in head and neck squamous cell carcinoma (HNSCC) from ESMO 2025, highlighting advances in both resectable locally advanced and recurrent/metastatic disease. Faculty experts first explore new data on perioperative and...

Faculty: Charles E. Geyer Jr., MD, FACP Faculty: Komal Jhaveri, MD, FACP This online educational activity equips clinicians with up-to-date, practice-changing insights from SABCS 2025. Experts review pivotal data across early-stage and metastatic breast cancer, including advances in HER2- and TROP2-directed ADCs, and discuss how these findings can meaningfully inform treatment selection. Participa...

Faculty: Stephen J. Greene, MD, FACC, FHFSA Faculty: Gianluigi Savarese, MD For ambulatory patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event, cardiologists continue to face a major clinical challenge: persistent and under-recognized cardiovascular (CV) risk. Despite adherence to quadruple guideline-directed medical therapy (GDMT) a...

Faculty: William Wierda, MD, PhD Faculty: Matthew S. Davids, MD, MMSc This activity focuses on optimizing first-line treatment strategies for patients with chronic lymphocytic leukemia (CLL). Drs. William Wierda and Matthew Davids discuss key distinctions between continuous BTK inhibitor therapy and time-limited venetoclax-based regimens, while highlighting considerations such as comorbidities, to...

Faculty: John C. Byrd, MD Faculty: William Mencia, MD, FACEHP Dr. John Byrd discusses current and emerging strategies for managing double-class-refractory chronic lymphocytic leukemia (CLL) in community settings. He emphasizes the importance of distinguishing resistance from intolerance to BTK inhibitors through clinical history and molecular testing. Data from the BRUIN trial support the use of p...

Faculty: Jennifer R. Brown, MD, PhD Faculty: William Mencia, MD, FACEHP This activity explores treatment sequencing strategies for chronic lymphocytic leukemia (CLL) following frontline therapy failure based on prior therapies, mechanisms of resistance, and minimal residual disease status. Dr. Jennifer Brown discusses how distinguishing between resistance and intolerance to BTK and BCL2 inhibitors...

Faculty: David Eichenbaum, MD In this didactic case presentation, Dr. David Eichenbaum discusses an 88-year-old patient with non-central geographic atrophy who received inappropriate bevacizumab treatment due to uncoordinated care after relocating seasonally. The case illustrates challenges that can arise in managing retinal disease across geographically distant sites. Dr. Eichenbaum emphasizes op...

Faculty: Esther Lee Kim, MD In this case-based presentation, Dr. Esther Lee Kim reviews a young patient with long-standing type 2 diabetes who presented with bilateral vision loss and was initially referred for possible retinal vein occlusion. The case underscores how demographic factors can inform the risk of rapid disease progression, even in the setting of a relatively controlled HbA1c. Dr. Kim...

Faculty: Deepak Sambhara, MD In this clinical discussion, Dr. Deepak Sambhara presents a case of a working-age man with severe non-proliferative diabetic retinopathy and diabetic macular edema. He details the diagnostic process using OCT and NIR imaging and explains how he engaged the patient in his treatment journey. Patient communication strategies are emphasized, as is a collaborative approach...

Faculty: David Chin Yee, MD, FASRS In this case-based discussion, Dr. David Chin Yee presents his challenges and outcomes when managing a patient with diabetic macular edema who initially declined treatment due to language limitations, cultural beliefs, and mistrust of medical interventions. The case highlights the implementation of culturally sensitive strategies and underscores the value of cult...

Faculty: María-Victoria Mateos, MD, PhD Faculty: Luciano Costa, M.D., Ph. D. This educational activity examines the growing evidence supporting bispecific antibodies in earlier treatment lines of multiple myeloma. Experts discuss the rationale for upstream use of bispecific antibodies and review key data from pivotal trials highlighting the evolving role for bispecific antibodies as early-line tre...

Faculty: Kevin J Harrington, PhD, FRCP, FRCR, FRSB Faculty: Cristina Rodriguez, MD This online educational activity provides clinicians with an in-depth review of the latest findings in head and neck squamous cell carcinoma (HNSCC) from ESMO 2025, highlighting advances in both resectable locally advanced and recurrent/metastatic disease. Faculty experts first explore new data on perioperative and...

Faculty: Charles E. Geyer Jr., MD, FACP Faculty: Komal Jhaveri, MD, FACP This online educational activity equips clinicians with up-to-date, practice-changing insights from SABCS 2025. Experts review pivotal data across early-stage and metastatic breast cancer, including advances in HER2- and TROP2-directed ADCs, and discuss how these findings can meaningfully inform treatment selection. Participa...

Faculty: Stephen J. Greene, MD, FACC, FHFSA Faculty: Gianluigi Savarese, MD For ambulatory patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event, cardiologists continue to face a major clinical challenge: persistent and under-recognized cardiovascular (CV) risk. Despite adherence to quadruple guideline-directed medical therapy (GDMT) a...

Faculty: William Wierda, MD, PhD Faculty: Matthew S. Davids, MD, MMSc This activity focuses on optimizing first-line treatment strategies for patients with chronic lymphocytic leukemia (CLL). Drs. William Wierda and Matthew Davids discuss key distinctions between continuous BTK inhibitor therapy and time-limited venetoclax-based regimens, while highlighting considerations such as comorbidities, to...

Faculty: John C. Byrd, MD Faculty: William Mencia, MD, FACEHP Dr. John Byrd discusses current and emerging strategies for managing double-class-refractory chronic lymphocytic leukemia (CLL) in community settings. He emphasizes the importance of distinguishing resistance from intolerance to BTK inhibitors through clinical history and molecular testing. Data from the BRUIN trial support the use of p...

Faculty: Jennifer R. Brown, MD, PhD Faculty: William Mencia, MD, FACEHP This activity explores treatment sequencing strategies for chronic lymphocytic leukemia (CLL) following frontline therapy failure based on prior therapies, mechanisms of resistance, and minimal residual disease status. Dr. Jennifer Brown discusses how distinguishing between resistance and intolerance to BTK and BCL2 inhibitors...

Faculty: David Eichenbaum, MD In this didactic case presentation, Dr. David Eichenbaum discusses an 88-year-old patient with non-central geographic atrophy who received inappropriate bevacizumab treatment due to uncoordinated care after relocating seasonally. The case illustrates challenges that can arise in managing retinal disease across geographically distant sites. Dr. Eichenbaum emphasizes op...

Faculty: Esther Lee Kim, MD In this case-based presentation, Dr. Esther Lee Kim reviews a young patient with long-standing type 2 diabetes who presented with bilateral vision loss and was initially referred for possible retinal vein occlusion. The case underscores how demographic factors can inform the risk of rapid disease progression, even in the setting of a relatively controlled HbA1c. Dr. Kim...

Faculty: Deepak Sambhara, MD In this clinical discussion, Dr. Deepak Sambhara presents a case of a working-age man with severe non-proliferative diabetic retinopathy and diabetic macular edema. He details the diagnostic process using OCT and NIR imaging and explains how he engaged the patient in his treatment journey. Patient communication strategies are emphasized, as is a collaborative approach...